Qiagen stock last at EUR 38.72 on September 30, 2026, down 1.02 percent

Qiagen stock was last at EUR 38.72 on September 30, 2026, at 5:37 p.m. CEST, down 1.02 percent versus the September 29 Xetra close. The company expanded its U.S. bloodstream infection testing portfolio.

Qiagen stock was last at EUR 38.72 on September 30, 2026, at 5:37 p.m. CEST, down 1.02 percent versus the EUR 39.12 Xetra close of September 29, 2026.

U.S. testing portfolio expanded

QIAGEN N.V. said U.S. laboratories now have access to its complete QIAstat-Dx bloodstream infection portfolio after the U.S. Food and Drug Administration cleared the QIAstat-Dx BCID GN Plus AMR Panel. The panel identifies 13 gram-negative bacterial targets and 18 antimicrobial resistance markers, with results delivered in about one hour, according to the Business Wire release.

Together with the previously cleared panel for gram-positive bacteria and fungi, the two tests cover 33 pathogen targets and 28 antimicrobial resistance markers, QIAGEN said in the same release.

Shareholder meeting planned

QIAGEN also announced an extraordinary general meeting for November 6, 2026, at which shareholders will vote on Jonathan M. Pratt’s appointment to the company’s Managing Board. Pratt became chief executive officer on September 1, 2026, and the meeting details were published by Business Wire.